| Structural optimization and pharmacological evaluation of inhibitors targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK) in … Q Zhou, AF Phoa, RH Abbassi, M Hoque, TA Reekie, JS Font, RM Ryan, ... Journal of Medicinal Chemistry 60 (5), 2052-2070, 2017 | 52 | 2017 |
| Development and biological evaluation of a photoactivatable small molecule microtubule-targeting agent A Döbber, AF Phoa, RH Abbassi, BW Stringer, BW Day, TG Johns, ... ACS medicinal chemistry letters 8 (4), 395-400, 2017 | 36 | 2017 |
| Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation L Munoz, ME Kavanagh, AF Phoa, B Heng, N Dzamko, EJ Chen, ... European Journal of Medicinal Chemistry 95, 29-34, 2015 | 35 | 2015 |
| Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling AF Phoa, S Browne, FMS Gurgis, MC Åkerfeldt, A Döbber, C Renn, ... Biochemical Pharmacology 98 (4), 587-601, 2015 | 17 | 2015 |
| MK2 inhibition induces p53-dependent senescence in glioblastoma cells AF Phoa, A Recasens, FMS Gurgis, TA Betts, SV Menezes, D Chau, ... Cancers 12 (3), 654, 2020 | 4 | 2020 |
| Targeting non-oncogenic kinases DYRK1A and MK2 in glioblastoma A Phoa University of Sydney, 2020 | | 2020 |
| Abstract A064: MK2 inhibition stabilizes wild-type and mutated p53 in glioblastoma cells and leads to different cellular responses AF Phoa, A Recasens, L Munoz Molecular Cancer Therapeutics 18 (12_Supplement), A064-A064, 2019 | | 2019 |
| PO-021 Inhibition of MK2 stabilises wild-type P53 and improves temozolomide efficacy in glioblastoma A Phoa, FMS Gurgis, TA Betts, BW Stringer, BW Day, N Lalaoui, L Munoz ESMO Open 3, A235-A236, 2018 | | 2018 |
| Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent R Abbassi, A Dobber, L Munoz, A Phoa, M Abadleh, BW Day, TG Johns, ... American Chemical Society, 2017 | | 2017 |
| Structural optimization and pharmacological evaluation of inhibitors targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK … R Abbassi, J Font Sadurni, M Hoque, M Kassiou, L Munoz, A Phoa, ... American Chemical Society, 2017 | | 2017 |
